You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ccRCC

Showing 1 - 25 of 113
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Contrast-enhanced CT-based Deep Learning Model for Preoperative

Recruiting
  • Predictive Ability of Contrast-enhanced CT-based Deep Learning Model in Patients With Localised ccRCC
  • +2 more
    • Chongqing, Chongqing, China
      Yingjie Xv
    Oct 12, 2023

    Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute

    Not yet recruiting
    • Advanced Clear Cell Renal Carcinoma (Ccrcc)
    • Papillary Renal Cell Carcinoma (Prcc)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)

    Recruiting
    • Neoplasms
    • +12 more
    • Nanjing, Jiangsu, China
      Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
    Oct 28, 2023

    ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

    Not yet recruiting
    • ccRCC
    • +20 more
    • (no location specified)
    Jul 6, 2023

    Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)

    Available
    • Clear Cell Renal Cell Carcinoma
    • 89Zr-DFO-girentuximab
    • Los Angeles, California
      UCLA
    Oct 12, 2023

    Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

    Recruiting
    • Cadonilimab
    • +2 more
    • Cadonilimab Combined With Lenvatinib
    • Guangzhou, Other (Non U.s.), China
      Sun Yat-sen University Cancer Center
    Nov 16, 2023

    Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

    Recruiting
    • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
    • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
    • Shanghai, Shanghai, China
      Shanghai Renji Hospital
    Sep 12, 2023

    Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic Trial in Iowa City (Selenomethionine (SLM),

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • Clear Cell Renal Cell Carcinoma Metastatic
    • Selenomethionine (SLM)
    • +2 more
    • Iowa City, Iowa
      University of Iowa Hospitals & Clinics
    Sep 19, 2022

    Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) Trial (KO-2806, Cabozantinib)

    Not yet recruiting
    • Solid Tumors With HRAS Alterations
    • +4 more
    • (no location specified)
    Aug 30, 2023

    Carcinoma, Renal Cell Trial in United States (Belzutifan)

    Recruiting
    • Carcinoma, Renal Cell
    • Boston, Massachusetts
    • +3 more
    Jan 27, 2023

    Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) Trial in Iowa City (Selenomethionine (SLM), Axitinib)

    Recruiting
    • Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
    • Iowa City, Iowa
      University of Iowa Hospitals and Clinics
    Sep 13, 2021

    Clear Cell Renal Cell Carcinoma, First-line Treatment Trial in Shanghai (AK104, axitinib)

    Not yet recruiting
    • Clear Cell Renal Cell Carcinoma
    • First-line Treatment
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 16, 2022

    Neoadjuvant Therapy Trial in Nanning (tislelizumab combined with axitinib)

    Active, not recruiting
    • Neoadjuvant Therapy
    • tislelizumab combined with axitinib
    • Nanning, Jiangsu, China
      Hongqian Guo
    Dec 13, 2021

    Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) Trial ([68Ga]Ga-DPI-4452,

    Not yet recruiting
    • Clear Cell Renal Cell Cancer (ccRCC)
    • +2 more
    • (no location specified)
    Jan 20, 2023

    ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial in United States (Oral NKT2152)

    Recruiting
    • ccRCC
    • +9 more
    • Oral NKT2152
    • Scottsdale, Arizona
    • +6 more
    Oct 17, 2022

    Advanced Solid Tumors, Solid Tumor, Solid Carcinoma Trial (Belzutifan)

    Active, not recruiting
    • Advanced Solid Tumors
    • +15 more
    • (no location specified)
    Sep 16, 2022

    Carcinoma, Renal Cell Trial in China (Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab)

    Recruiting
    • Carcinoma, Renal Cell
    • Pembrolizumab
    • +3 more
    • Beijing, Beijing, China
    • +16 more
    Jun 2, 2023

    Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, NSCLC (NSCLC) Trial in United States (CB-839, Nivolumab)

    Completed
    • Clear Cell Renal Cell Carcinoma (ccRCC)
    • +2 more
    • Scottsdale, Arizona
    • +16 more
    Aug 16, 2021

    ccRCC, RCC, Kidney Cancer Trial in United States (MK-3795, Nivolumab, Cabozantinib)

    Active, not recruiting
    • ccRCC
    • +4 more
    • Los Angeles, California
    • +24 more
    Jul 18, 2022

    Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)

    Terminated
    Has Results
    • Solid Tumor
    • +6 more
    • Birmingham, Alabama
    • +8 more
    Feb 16, 2022

    Carcinoma, Renal Cell Trial in Worldwide (DFF332, RAD001, PDR001)

    Recruiting
    • Carcinoma, Renal Cell
    • Duarte, California
    • +10 more
    Jun 13, 2022

    Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial in United

    Terminated
    Has Results
    • Clear Cell Renal Cell Carcinoma
    • +4 more
    • Ascorbic Acid
    • Pazopanib Hydrochloride
    • Peoria, Illinois
    • +4 more
    Mar 18, 2022

    Clear Cell Renal Cell Carcinoma Trial in Worldwide (89Zr-girentuximab)

    Recruiting
    • Clear Cell Renal Cell Carcinoma
    • 89Zr-girentuximab
    • Duarte, California
    • +29 more
    Aug 4, 2021

    Advanced Cancer, Clear Cell Renal Cell Carcinoma Trial in Houston (177Lu girentuximab, Nivolumab, Cabozantinib)

    Not yet recruiting
    • Advanced Cancer
    • Clear Cell Renal Cell Carcinoma
    • 177Lu girentuximab
    • +3 more
    • Houston, Texas
      MD Anderson Cancer Center
    Dec 15, 2022

    Renal Cell Carcinoma Trial (Sunitinib)

    Not yet recruiting
    • Renal Cell Carcinoma
    • (no location specified)
    Sep 11, 2023